Loading...
•
Mar 31, 2021
Bioxcel Therapeutics Q1 2021 Earnings Report
Reported first quarter results and provided business update.
Key Takeaways
BioXcel Therapeutics reported a net loss of $26.4 million for the first quarter of 2021. As of March 31, 2021, cash and cash equivalents totaled approximately $194 million. The company received Breakthrough Therapy designation for BXCL501 for the acute treatment of agitation associated with dementia and submitted NDA to FDA for BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders.
Granted FDA Breakthrough Therapy designation for BXCL501 for the acute treatment of agitation associated with dementia; registrational program expected to begin in 2H 2021
Submitted NDA to FDA for BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders
Strategic geographic market extension plans for BXCL501 underway; expects to submit MAA to EMA for the acute treatment of agitation associated with schizophrenia and bipolar disorders in 2H 2021
Commercial readiness preparations ramping-up for potential approval of BXCL501 in first two indications
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...